Myasthenia gravis (MG) treatment: pyridostigmine

Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .

Myasthenia gravis (MG) treatment: pyridostigmine. Pyridostigmine showed better efficacy than placebo in a randomized control trial.

Efficacy

  • Pyridostigmine showed better efficacy than placebo in a randomized control trial

Dosing regime

Locked: subscribe to see this section.

Precautions

Locked: subscribe to see this section.

Side effects

Locked: subscribe to see this section.

Treatment of side effects

Locked: subscribe to see this section.

References

  1. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17:893-902.
  2. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016; 87:419-425.
  3. Remijn-Nelissen L, Bakker WR, van den Hout WB, et al. Efficacy of pyridostigmine in myasthenia gravis: a randomized, double-blind, placebo-controlled crossover trial. Neurology 2026; 106:e214865.
  4. Donskov AO, Vinge L, Axelsen SM, Andersen H. Overactive bladder in patients with myasthenia gravis-A cross-sectional population-based study. Acta Neurol Scand 2021; 144:76-80.
  5. Ceccanti M, Libonati L, Ruffolo G, et al. Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study. Front Pharmacol 2022; 13:982434.

Related checklists

Loading...